2025/03/14 更新

写真a

ナガイ ナオヤ
長井 尚哉
NAGAI Naoya
所属
医学部附属病院 放射線部 病院助教
職名
病院助教
 

論文 6

  1. Comparing Pain Response to Palliative Radiotherapy in Painful Bone Metastases vs. Painful Non-Bone Lesions: A Secondary Analysis of a Prospective Observational Study 査読有り

    Koide, Y; Shindo, Y; Nagai, N; Kitagawa, T; Aoyama, T; Shimizu, H; Hashimoto, S; Tachibana, H; Kodaira, T

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   120 巻 ( 2 ) 頁: E246 - E247   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  2. Stereotactic Body Radiation Therapy for Oligometastatic Non -Spine Bone Metastases: A Retrospective Two-Center Study 査読有り

    Shindo, Y; Koide, Y; Nagai, N; Kitagawa, T; Aoyama, T; Shimizu, H; Hashimoto, S; Tachibana, H; Kodaira, T

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   120 巻 ( 2 ) 頁: E272 - E273   2024年10月

     詳細を見る

    記述言語:英語  

    Web of Science

  3. Impact of Concurrent Antibody-Drug Conjugates and Radiotherapy on Symptomatic Radiation Necrosis in Breast Cancer Patients with Brain Metastases: A Multicenter Retrospective Study 査読有り

    Koide, Y; Nagai, N; Ito, M; Adachi, S; Shindo, Y; Aoyama, T; Shimizu, H; Hashimoto, S; Tachibana, H; Kodaira, T

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   120 巻 ( 2 ) 頁: E246 - E246   2024年10月

     詳細を見る

    記述言語:英語  

    Web of Science

  4. The current state and future perspectives of radiotherapy for cervical cancer. 査読有り Open Access

    Yamada T, Kawamura M, Oie Y, Kozai Y, Okumura M, Nagai N, Yanagi Y, Nimura K, Ishihara S, Naganawa S

    The journal of obstetrics and gynaecology research   50 Suppl 1 巻 ( S1 ) 頁: 84 - 94   2024年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Obstetrics and Gynaecology Research  

    Radiotherapy is an effective treatment method for cervical cancer and is typically administered as external beam radiotherapy followed by intracavitary brachytherapy. In Japan, center shielding is used in external beam radiotherapy to shorten treatment time and reduce the doses delivered to the rectum or bladder. However, it has several challenges, such as uncertainties in calculating the cumulative dose. Recently, external beam radiotherapy has been increasingly performed with intensity-modulated radiotherapy, which reduces doses to the rectum or bladder without center shielding. In highly conformal radiotherapy, uncertainties in treatment delivery, such as inter-fractional anatomical structure movements, affect treatment outcomes; therefore, image-guided radiotherapy is essential for appropriate and safe performance. Regarding intracavitary brachytherapy, the use of magnetic resonance imaging-based image-guided adaptive brachytherapy is becoming increasingly widespread because it allows dose escalation to the tumor and accurately evaluates the dose delivered to the surrounding normal organs. According to current evidence, a minimal dose of D90% of the high-risk clinical target volume is significantly relevant to local control. Further improvements in target coverage have been achieved with combined interstitial and intracavity brachytherapy for massive tumors with extensive parametrical involvement. Introducing artificial intelligence will enable faster and more accurate generation of brachytherapy plans. Charged-particle therapies have biological and dosimetric advantages, and current evidence has proven their effectiveness and safety in cervical cancer treatment. Recently, radiotherapy-related technologies have advanced dramatically. This review provides an overview of technological innovations and future perspectives in radiotherapy for cervical cancer.

    DOI: 10.1111/jog.15998

    Open Access

    Web of Science

    Scopus

    PubMed

  5. Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study. 査読有り

    Koide Y, Nagai N, Adachi S, Ito M, Kawamura M, Ito M, Ito F, Shindo Y, Aoyama T, Shimizu H, Hashimoto S, Tachibana H, Kodaira T

    Journal of neuro-oncology   168 巻 ( 3 ) 頁: 415 - 423   2024年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Neuro-Oncology  

    Aim: We aimed to investigate the impact of concurrent antibody–drug conjugates (ADC) and radiotherapy on symptomatic radiation necrosis (SRN) in breast cancer patients with brain metastases (BM). Methods: This multicenter retrospective study uses four institutional data. Eligibility criteria were histologically proven breast cancer, diagnosed BM with gadolinium-enhanced MRI, a Karnofsky performance status of 60 or higher, and radiotherapy for all BM lesions between 2017 and 2022. Patients with leptomeningeal dissemination were excluded. Concurrent ADC was defined as using ADC within four weeks before or after radiotherapy. The cumulative incidence of SRN until December 2023 with death as a competing event was compared between the groups with and without concurrent ADC. Multivariable analysis was performed using the Fine-Gray model. Results: Among the 168 patients enrolled, 48 (29%) received ADC, and 19 (11%) had concurrent ADC. Of all, 36% were HER2-positive, 62% had symptomatic BM, and 33% had previous BM radiation histories. In a median follow-up of 31 months, 18 SRNs (11%) were registered (11 in grade 2 and 7 in grade 3). The groups with and without concurrent ADC had 5 SRNs in 19 patients and 13 SRNs in 149, and the two-year cumulative incidence of SRN was 27% vs. 7% (P = 0.014). Concurrent ADC was associated with a higher risk of SRN on multivariable analysis (subdistribution hazard ratio, 3.0 [95% confidence interval: 1.1–8.3], P = 0.030). Conclusions: This study suggests that concurrent ADC and radiotherapy are associated with a higher risk of SRN in HER2-positive breast cancer patients.

    DOI: 10.1007/s11060-024-04681-8

    Web of Science

    Scopus

    PubMed

  6. Palliative radiotherapy for painful non-bone lesions in patients with advanced cancer: a single center retrospective study. 査読有り Open Access

    Shindo Y, Koide Y, Nagai N, Kitagawa T, Aoyama T, Shimizu H, Hashimoto S, Tachibana H, Kodaira T, Ishihara S, Naganawa S

    Japanese journal of radiology   42 巻 ( 6 ) 頁: 656 - 661   2024年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Japanese Journal of Radiology  

    Purpose: This retrospective study aimed to assess the efficacy and safety of palliative radiotherapy for painful non-bone lesions in patients with advanced cancer. Materials and methods: We enrolled patients with painful non-bone lesions who underwent conventional palliative radiotherapy between September 2018 and September 2022. The treatment targets included primary tumor lesions, lymph node metastases, non-bone hematogenous metastases, and other lesions. The primary endpoint was the overall pain response rate in evaluable patients, determined based on the International Consensus Pain Response Endpoint criteria. The secondary endpoints included overall survival, pain recurrence, and adverse events. Results: Of the 420 screened patients, 142 received palliative radiotherapy for painful non-bone lesions, and 112 were evaluable. A pain response was achieved in 67 patients (60%) of the 112 evaluable patients within a median of 1.2 months. Among these patients, 25 exhibited complete response, 42 partial response, 18 indeterminate response, and 27 pain progression. The median survival time was 5.5 months, recorded at a median follow-up of 6.0 months, during which 67 patients died. Multivariate analysis identified poor performance status scores of 2–4, opioid use, and re-irradiation as independent factors associated with a reduced likelihood of achieving a pain response. Pain recurrence occurred in 18 patients over a median of 4.1 months. Seventeen patients had grade 1–2 adverse events, while none experienced grade 3 or higher toxicity. Conclusion: Palliative radiotherapy can potentially be a safe and well-tolerated modality for managing painful non-bone lesions, with a low rate of adverse events.

    DOI: 10.1007/s11604-024-01536-0

    Open Access

    Web of Science

    Scopus

    PubMed

▼全件表示